N = 173 (%) | |
---|---|
Age (median, range) | 57 (34–88) |
SEX | |
Male | 116 (67) |
Female | 57 (33) |
RACE | |
African American | 90 (52) |
White | 83 (48) |
Performance status (PS) | |
0-1 | 130 (76) |
2-4 | 42 (24) |
Histology | |
Adenocarcinoma | 91 (52) |
Non-adenocarcinoma | 82 (47) |
Number of metastatic sites | |
1-2 | 93 (54) |
>2 | 80 (46) |
Chemotherapy | |
No chemo | 59 (34) |
Any chemo | 114 (66) |
First response assessment | |
Response to chemotherapy | 41 (23) |
Stable disease | 24 (14) |
Progression | 39 (23) |
Decline in performance status | 69 (40) |
Survival (months) | |
Median progression free survival | 3.7 |
Median overall survival | 5.1 |